Wyeth Sonata Short-Term Psychomotor Symptoms Allows Mid-Night Dosing
Executive Summary
The short-term psychomotor effects of Wyeth-Ayerst's insomnia drug Sonata (zaleplon) allow late night dosing without significant lingering effects the following day.
You may also be interested in...
Sanofi-Synthelabo Looking Long (In Dosing), Deep (In U.S. Market) For Ambien
Sanofi-Synthelabo is considering extending the half-life of its lead product Ambien (zolpidem) in an effort to differentiate the hypnotic agent from the recently approved Wyeth-Ayerst competitor drug Sonata, Sanofi-Synthelabo Chief Operating Officer Herve Guerin indicated at Sept. 2 meeting in London.
Sanofi-Synthelabo Looking Long (In Dosing), Deep (In U.S. Market) For Ambien
Sanofi-Synthelabo is considering extending the half-life of its lead product Ambien (zolpidem) in an effort to differentiate the hypnotic agent from the recently approved Wyeth-Ayerst competitor drug Sonata, Sanofi-Synthelabo Chief Operating Officer Herve Guerin indicated at Sept. 2 meeting in London.
Pediatric Combo Drugs Could Rely On Individual Active Ingredient Studies
FDA may allow sponsors of combination drugs to rely on data from studies of individual drug components for pediatric submissions.